Screening for prostate cancer without digital rectal examination and transrectal ultrasound: Results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam

The Prostate ◽  
2006 ◽  
Vol 66 (6) ◽  
pp. 625-631 ◽  
Author(s):  
Claartje Gosselaar ◽  
Monique J. Roobol ◽  
Stijn Roemeling ◽  
Stijn H. de Vries ◽  
Ingrid van der Cruijsen-Koeter ◽  
...  
2017 ◽  
Vol 24 (2) ◽  
Author(s):  
Christiano Tansol ◽  
Ferry Safriadi

Objective: To compare the validated calculators of Indonesian Prostate Cancer Risk Calculator  (IPCRC) vs Korean Prostate Cancer Risk Calculator (KPCRC) vs Prostate Cancer Prevention Trial Risk Calculator (PCPT-RC) vs European Randomized Study of Screening for Prostate Cancer Risk Calculator (ERSPC-RC) in predicting prostate cancer in our patients at Hasan Sadikin Hospital Bandung. Material & methods: This study is a prospective study conducted from August 2014 – December 2015 at Urology Clinic at Hasan Sadikin Hospital that included all patients with BPH or suspected PCa who have been undergoing prostate biopsy. Variables such as age, PSA level, prostate volume (transabdominal or transrectal ultrasound) and digital rectal examination (DRE) finding were recorded. Risk calculation was generated using each risk calculator. Data were analyzed using Chi-square analysis, Kolmogorov-Smirnov, and finally receiver operating characterisitic (ROC) curve. All statistical analyses were performed with SPSS version 20.  Results: There were 89 BPH and 43 PCa patients between August 2014 – December 2015. The mean age, PSA and prostate volume are 65.78 ± 8.33 years; 121.16 ± 375.76ng/ml; 55.86 ± 31.9ml respectively. Abnormal DRE was found in 27 PCas and 4 BPHs. Receiver operator curve analysis of IPCRC showed AUC 0.861 vs KPCRC (AUC=0.779) vs ERSPC-RC (AUC=0.745) vs PCPT-RC (AUC=0.794) vs PSA (AUC 0.794), sensitivity 81.4% and specificity 71.9% with cut-off point 19.67 for the IPCRC in predicting the prostate cancer in our center. Conclusion: IPCRC is better than KPCRC, PCPT-RC and ERSPC-RC in predicting prostate cancer in our center.


1992 ◽  
Vol 59 (4) ◽  
pp. 52-55
Author(s):  
M. Moretti ◽  
A. Cichero ◽  
P. Pittaluga ◽  
M. Varaldo ◽  
Aldo V. Bono ◽  
...  

PSA is commonly used in diagnosing prostate cancer but it lacks both specificity and sensitivity; PSA values rise in benign prostatic affections and up to 30% prostate cancers show normal PSA values. Preliminary reports indicate that PSA DENSITY (PSAD), i.e. PSA/prostate-volume ratio, can improve specificity of PSA in diagnosing prostate cancer. We considered PSAD in 55 patients of 160 observed for prostatism: all of them underwent digital rectal examination, transrectal ultrasound and multiple biopsies of the gland. We found cancer in 19 patients (PSAD ranging from 0.17 to 1.77, with a mean value of 0.45), 26 prostatic hyperplasia (PSAD from 0.003 to 0.75, with a mean of 0.13), 6 dysplasia (PSAD from 0.07 to 0.30, with a mean of 0.19). In our experience PSAD > 0.17 or mean value > 0.45 indicate cancer in the absence of significant digital rectal examination and ultrasound findings or normal and borderline PSA values.


Sign in / Sign up

Export Citation Format

Share Document